AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Iran-Israel Missile Strikes Continue Amid Mixed Signals on U.S.-Iran Diplomacy 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
9 Tips for Avoiding Tax Season Cyber Scams 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Australia's Inflation Eases in February but Core Pressures Persist 
Samsung Group is currently negotiating to acquire Biogen Inc., the American biotech company headquartered in Cambridge, Massachusetts. If the talks turn out to be successful, it will be the South Korean manufacturing conglomerate's biggest transaction ever.
Samsung Group is really interested in the mega-deal proposal from Biogen Inc., and this is set to become its largest acquisition. In 2016, the company set a record for its largest transaction ever after buying Harman, an American electronics systems maker for vehicles, for $8 billion. Now, its possible acquisition of the biotech firm will top this amount by more than five times over.
According to The Korea Economic Daily, Biogen Inc. spoke to Samsung to offer some of its shares that could be worth over ₩50 trillion or about $42 billion, including the control premium. The biotech firm's market cap at the moment is moderately less than $35 billion.
An investment banking source revealed on Wednesday, Dec. 29, that Samsung Group may buy the US-based drugmaker that specializes in neurological diseases, including dementia and Alzheimer's. "Samsung is at the negotiating table with the sell-side to acquire Biogen," a senior official at a global investment bank told KED.
In case the stake acquisition turns out to be successful, Samsung will become one of the top-ranking global biotechnology companies. It will also be able to expand its pharmaceutical business and do more aside from biosimilar treatment drugs and manufacturing deals. As for Biogen, it is also expected to steadily make high operating profits once the deal is sealed.
"Samsung is nurturing bio business as a new growth engine," another insider stated. "Acquiring Biogen will create an opportunity to take a quantum leap."
If the acquisition talks failed, it was reported that Samsung would attempt to buy back the remaining stake owned by Biogen in Samsung Bioepis, their biosimilar joint venture. Meanwhile, the response to the acquisition news was good so far as Biogen's stock went up after the report was published.
Market Watch reported that Biogen's shares increased 8.9 percent in the afternoon trading on Wednesday, just after it was reported that Samsung Group is on the negotiation table with the US-based drugmaker to purchase stakes in the company that is valued at around $42 billion.
